WHO Expert Committee on Drug Dependence – WHO Technical Report Series, No. 915 – Thirty-third Report
(2003; 31 pages) [French] [Spanish] Ver el documento en el formato PDF
Índice de contenido
Ver el documento1. Introduction
Ver el documento2. Scheduling criteria
Abrir esta carpeta y ver su contenido3. Critical review of psychoactive substances
Cerrar esta carpeta4. Pre-review of psychoactive substances
Ver el documento4.1 Ketamine (INN)
Ver el documento4.2 Zaleplon (INN)
Ver el documento4.3 Zopiclone (INN)
Ver el documento4.4 Butorphanol (INN)
Ver el documento4.5 Oripavine
Ver el documento4.6 Khat
Ver el documento5. Terminology used in reporting abuse-related adverse drug reactions
Ver el documento6. Other matters
Ver el documentoAcknowledgements
Ver el documentoReferences
Ver el documentoAnnex Terminology used in reporting abuse-related adverse drug reactions

4.4 Butorphanol (INN)

Butorphanol, chemical name (-)-17-(cyclobutylmethyl)morphinan-3,14-diol, was reviewed by a WHO Review Group in 1981 (11) and 1983 (6), and at the twenty-fifth meeting of the Committee (7), which did not recommend international control.

Butorphanol is a synthetically derived opioid compound with mixed agonist-antagonist properties at the μ-opioid receptor. It exerts its analgesic effect by acting as an agonist at the κ-opioid receptors. Butorphanol has a profile of actions similar to those produced by pentazocine. Two to three milligrams of parenterally administered butorphanol produce analgesia and respiratory depression approximately equal to that caused by 10 mg of morphine. There have been a significant number of reports of abuse, withdrawal syndrome and dependence related to butorphanol and this drug ranks first in the list of all drugs for which drug dependence has been reported as an adverse drug reaction to the WHO International Drug Monitoring Programme. Most of these reports originated from Canada, Italy, the United Kingdom and the USA. In Canada, drug-seeking behaviour has been reported in association with the use and abuse of butorphanol nasal spray. At least four countries have taken regulatory actions to control butorphanol, indicating that its abuse is considered as a significant problem in more than one country.


On the basis of the above data the Committee recommended the critical review of butorphanol.

Ir a la sección anterior
Ir a la siguiente sección
El Portal de Información - Medicamentos Esenciales y Productos de Salud de la OMS fue diseñado y es mantenido por la ONG Human Info. Última actualización: le 29 octubre 2018